KPIs & Operating Metrics(New)
Breakdown Of AssetsContractual ObligationsCost Of Goods SoldCost Of Goods Sold By SegmentEmployee StatisticsGross Margin %Gross Margin By Segment %Gross ProfitGross Profit By SegmentIncome (Loss) Before Income Tax By RegionLong Lived Assets By Geography AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Operating Income (Loss) By SegmentOperating Income (Loss) By Segment AnnualOperating Margin By Segment %Operating Margin By Segment Annual %Opex As A % Of Total Revenue %OPEX SegregationProperty, Plant, And Equipment, NetRevenue By Category AvkareRevenue By Category Avkare AnnualRevenue By Category GenericsRevenue By Category Generics AnnualRevenue By Category SpecialtyRevenue By Category Specialty AnnualRevenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Gross Profit (2017 - 2025)

Historic Gross Profit for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $274.0 million.

  • Amneal Pharmaceuticals' Gross Profit rose 163.82% to $274.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 1389.07%. This contributed to the annual value of $1.0 billion for FY2024, which is 2435.8% up from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Gross Profit stood at $274.0 million for Q3 2025, which was up 163.82% from $286.3 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' 5-year Gross Profit high stood at $286.3 million for Q2 2025, and its period low was $166.4 million during Q4 2021.
  • For the 5-year period, Amneal Pharmaceuticals' Gross Profit averaged around $221.6 million, with its median value being $215.4 million (2022).
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Gross Profit surged by 4860.28% in 2021, and later crashed by 1186.74% in 2023.
  • Over the past 5 years, Amneal Pharmaceuticals' Gross Profit (Quarter) stood at $166.4 million in 2021, then grew by 29.44% to $215.4 million in 2022, then decreased by 11.87% to $189.8 million in 2023, then surged by 38.48% to $262.9 million in 2024, then rose by 4.22% to $274.0 million in 2025.
  • Its Gross Profit stands at $274.0 million for Q3 2025, versus $286.3 million for Q2 2025 and $255.9 million for Q1 2025.